 Inozyme Pharma Inc NASDAQ: INZY has dosed the first patient in its Phase 12 trial of INZ-701 in adult patients with ABCC6 Deficiency. Also, the second cohort in the ongoing Phase 12 clinical trial in ENPP1 Deficiency has been fully enrolled. 